WHY IT MATTERS: Patients managing metabolic syndrome, obesity, or early-stage fatty liver disease may want to discuss cannabinoid-based options with their physician as this area of research continues to develop. CLINICAL OVERVIEW: Preclinical and emerging clinical research suggests that certain cannabinoids, particularly CBD and to some extent THC, may help reduce hepatic fat accumulation and inflammation associated with metabolic-associated steatotic liver disease, formerly known as non-alcoholic fatty liver disease. These compounds appear to interact with the endocannabinoid system’s CB1 and CB2 receptors in hepatic tissue, with CB2 activation generally showing protective anti-inflammatory effects while CB1 activation may carry more complex metabolic implications.
Study reveals cannabis compounds reduce threat of fatty liver disease | Health – News-Topic
WHY IT MATTERS: For the millions of patients with fatty liver disease who have limited pharmacological options, cannabinoid-based therapies could represent a meaningful new direction in treatment if ongoing clinical trials confirm these early findings. CLINICAL OVERVIEW: Emerging research suggests that cannabinoids, including both THC and CBD, may play a protective role against the development and progression of non-alcoholic fatty liver disease (NAFLD) by modulating hepatic inflammation, lipid metabolism, and fibrotic pathways through the endocannabinoid system. The liver expresses both CB1 and CB2 receptors, and while CB1 activation has historically been associated with pro-steatotic effects, selective CB2 stimulation appears to confer anti-inflammatory and antifibrotic benefits.